Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.50.
A number of analysts have recently issued reports on MGX shares. BMO Capital Markets lowered their price target on Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research report on Thursday, September 5th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Metagenomi in a research report on Friday, September 6th.
View Our Latest Stock Analysis on MGX
Institutional Trading of Metagenomi
Metagenomi Trading Down 6.8 %
Shares of NASDAQ:MGX opened at $2.45 on Friday. The business’s 50 day moving average price is $3.45 and its 200-day moving average price is $6.06. Metagenomi has a 1 year low of $2.41 and a 1 year high of $12.74.
Metagenomi (NASDAQ:MGX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.30. The company had revenue of $20.01 million for the quarter, compared to analysts’ expectations of $14.80 million. Research analysts predict that Metagenomi will post -3.04 EPS for the current year.
Metagenomi Company Profile
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Recommended Stories
- Five stocks we like better than Metagenomi
- What is a support level?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Options Trading – Understanding Strike Price
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is Forex and How Does it Work?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.